Plant Name: Maprounea guianensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; HSD17B1; CBR1; AKR1B1; HSD17B10; | |
| CDK6; | |
| CA2; CA1; CA12; CA9; CA7; CA4; | |
| CTSD; | |
| HIF1A; | |
| ABCG2; | |
| XDH; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | CTSD | Cathepsin D | P07339 | CHEMBL2581 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.443E-14 | 3.950E-10 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.771E-13 | 2.053E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.667E-12 | 9.678E-09 | CA1, CA12, CA2, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.199E-12 | 1.984E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4, XDH |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 9.606E-12 | 2.092E-08 | CA1, CA12, CA2, CA4, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.287E-11 | 4.150E-08 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.019E-11 | 5.058E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.985E-11 | 6.785E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.067E-10 | 1.162E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.512E-10 | 6.291E-07 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.894E-09 | 3.631E-06 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 3.222E-07 | 1.594E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.571E-06 | 1.056E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 3.766E-06 | 1.464E-03 | CYP19A1, CYP1A2, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 4.066E-06 | 1.502E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 4.066E-06 | 1.502E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 7.540E-06 | 2.648E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 8.126E-06 | 2.722E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1.108E-05 | 3.547E-03 | AKR1B1, CBR1, HSD17B1, HSD17B10 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 1.295E-05 | 4.085E-03 | AKR1B1, CA2, CYP1A1, CYP1A2, CYP1B1, HIF1A |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.353E-05 | 4.210E-03 | CYP1A1, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.028E-05 | 6.051E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004064; arylesterase activity | 2.028E-05 | 6.051E-03 | CA1, CA2 |
| BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 2.838E-05 | 8.131E-03 | CYP1A2, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.962E-15 | 7.580E-11 | CA1, CA12, CA2, CA4, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.395E-14 | 7.395E-13 | CA12; CA1; CA2; CA4; CA7; CA9 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.485E-12 | 9.236E-11 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 4.429E-11 | 7.824E-10 | HSD17B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.842E-10 | 2.441E-09 | CYP2C9; CBR1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.341E-08 | 2.951E-07 | CYP2C9; CBR1; HSD17B1; CYP1A2; CYP1A1; AKR1B1; CYP2C19; CYP3A4; CYP19A1; HSD17B10; XDH |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 2.955E-07 | 2.237E-06 | HSD17B1; CYP1A1; CYP1B1; CYP19A1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.096E-08 | 2.951E-07 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 8.588E-07 | 5.689E-06 | CYP2C9; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.093E-06 | 6.438E-06 | CYP2C9; CYP1A2; CYP3A4; CYP2C19 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.277E-05 | 6.151E-05 | CYP1A2; CYP1A1; CYP1B1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.807E-05 | 2.123E-04 | CYP2C9; CBR1; CYP2C19 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.215E-05 | 2.942E-04 | CA2; CYP3A4; ABCG2 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.270E-03 | 4.486E-03 | CYP3A4; XDH |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 7.282E-03 | 2.412E-02 | CYP2C9; CYP2C19 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 3.154E-04 | 1.194E-03 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 1.262E-05 | 6.151E-05 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | XDH; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; CA4 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1 |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; CA1; CA9 |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | CTSD |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CTSD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1 |